Citations in PubMed

Primary Citation PubMed: 15710326 Citations in PubMed

PDB ID Mentions in PubMed Central Article count: 5

Citations in PubMed

This linkout lists citations, indexed by PubMed, to the Primary Citation for this PDB ID.

PDB ID Mentions in PubMed Central

Data mentions are occurrences of PDB IDs in the full text articles from the PubMedCentral Open Access Subset of currently about 1 million articles. For each article, the sentences containing the PDB ID are listed. Article titles can be filtered by keywords and sorted by year.

  • 3 per page
  • 5 per page
  • 10 per page
  • view all
  • Publication Year
  • Ascending
  • Descending

A medicinal chemist's guide to molecular interactions.

(2010) J Med Chem 53

PubMed: 20345171 | PubMedCentral: PMC2905122 | DOI: 10.1021/jm100112j

Figure 11 (a) Fluorine interactions in the complex between nilotinib and abl kinase (PDB code 3cs9 ).

Publication Year: 2010


KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms.

(2013) Nucleic Acids Res 41

PubMed: 23193279 | PubMedCentral: PMC3531076 | DOI: 10.1093/nar/gks1218

To facilitate the observation, we constructed a pseudostructure with 14 anchors by combining six representative kinase structures (i.e. PDB codes 1AQ1 [CDK2], 3EQH [MAP2K1], 1O6K [AKT2], 2WGJ [MET], 3... S9 [ABL1] and 2HZ0 [ABL1]) and by eliminating the collision residues located near the bound inhibitors.

(B) Identification of the template candidate ABL1 (PDB code 3CS9) with inhibitor nilotinib of the query using BLASTP to scan the structural template database.

The template ABL1-nilotinib complex (PDB code 3CS9) with conformation type E (DFG-out and A-loop-in), which binds to the type II inhibitor nilotinib approved for the treatment of drug-resistant CML ( 49 , 50 ), was selected as an example.

(C) Residues, pocket surfaces and nilotinib reference poses of ABL1, MAPK14, EPHA7 and FES using the ABL1-nilotinib structure (PDB code 3CS9).

Publication Year: 2013


Overcoming AC220 resistance of FLT3-ITD by SAR302503.

(2013) Blood Cancer J 3

PubMed: 23995047 | PubMedCentral: PMC3763391 | DOI: 10.1038/bcj.2013.40

10 We used the crystal structure of FLT3 crystallized in an inactive conformation and with related inhibitor−kinase complexes: for example, ABL complexed with nilotinib in closed and inactive ... onformation (PDB:3CS9); Ppy-A bound to the active conformation of ABL-T315I (PDB:2Z60); and JAK2 bound to isoquinoline in active conformation (PDB:2B7A).

( a ) Ribbon depiction of a structural model of FLT3-SAR302503 using the coordinates of the inactive FLT3 kinase (PDB:3CS9), ABL (PDB:2Z60) and JAK2 (PDB:2B7A).

Publication Year: 2013


PubMed ID is not available.

Published in 2014

PubMedCentral: PMC4086741

(d) Model of binding of nilotinib within the active site of BCR-ABL kinase based on the cocrystal structure of nilotinib–ABL kinase (PDB ID 3CS9).

Publication Year: 2014


PubMed ID is not available.

Published in 2015

PubMedCentral: PMC4468085

The following crystal structures were simulated: the inactive ABL structure bound with Nilotinib (pdb id 3CS9) and Ponatinib (pdb id 3OXZ); the active-like ABL structure bound with Bosutinib (3UE4), t... e active SRC structure bound with Bosutinib (pdb id 4NMXO); Dasatinib complexed with the active structures of EPHA4 (pdb id 2Y6O); LYN (pdb id 2ZVA), P38 (pdb id 3LFA), BTK (pdb id 3K54); Dasatinib binds with the inactive structures of BMX (pdb id 3SXR) and BTK kinases (pdb id 3OCT).

Conformational dynamics profiles are shown for the crystal structures of the ABL complexes with type 2 inhibitors Nilotinib (pdb id 3CS9, panel A) and Ponatinib (pdb id 3OXZ, panel B).

Publication Year: 2015